ANAVEX LIFE SCIENCES CORP.
AVXLDrugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AVXL Earnings Report
EPS Est: $-0.08 | FQ end 2026-06
How AVXL's past catalysts played out
ANAVEX2-73
Alzheimer's Disease
Mid dose ANAVEX2-73
Alzheimer Disease
ANAVEX2-73 oral liquid
Rett Syndrome
High dose ANAVEX2-73
Parkinsons Disease With Dementia
ANAVEX2-73 Oral
Alzheimer's Disease
ANAVEX3-71 oral capsules
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ANAVEX2-73 | Phase 3 | Alzheimer's Disease | - | - |
Mid dose ANAVEX2-73 | Phase 3 | Alzheimer Disease | - | - |
ANAVEX2-73 oral liquid | Phase 3 | Rett Syndrome | - | - |
High dose ANAVEX2-73 | Phase 3 | Parkinsons Disease With Dementia | - | - |
ANAVEX2-73 Oral | Phase 2 | Alzheimer's Disease | - | - |
ANAVEX3-71 oral capsules | Phase 2 | Schizophrenia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ANAVEX LIFE SCIENCES CORP.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in ANAVEX LIFE SCIENCES CORP.'s (AVXL) pipeline across Phase 3, Phase 2. Its lead program is ANAVEX2-73 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ANAVEX LIFE SCIENCES CORP.'s next FDA catalyst?→
ANAVEX LIFE SCIENCES CORP.'s (AVXL) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVXL biotech catalysts?→
Add AVXL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ANAVEX LIFE SCIENCES CORP.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.